UBS Group Forecasts Strong Price Appreciation for Medline (NASDAQ:MDLN) Stock

Medline (NASDAQ:MDLN) had its target price raised by research analysts at UBS Group from $48.00 to $57.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price target would suggest a potential upside of 14.90% from the company’s previous close.

A number of other equities analysts also recently weighed in on the company. Leerink Partners set a $56.00 price target on Medline in a research report on Wednesday. Bank of America initiated coverage on Medline in a report on Monday, January 12th. They set a “buy” rating and a $50.00 target price on the stock. BMO Capital Markets raised their price target on Medline from $45.00 to $54.00 and gave the company an “outperform” rating in a report on Thursday. Robert W. Baird initiated coverage on shares of Medline in a research report on Monday, January 12th. They set an “outperform” rating and a $48.00 price objective for the company. Finally, Rothschild & Co Redburn set a $42.00 price objective on shares of Medline in a research report on Monday, January 12th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Medline currently has an average rating of “Moderate Buy” and an average price target of $49.69.

Medline Trading Up 3.0%

MDLN traded up $1.43 during trading on Thursday, reaching $49.61. 1,568,604 shares of the stock were exchanged, compared to its average volume of 3,332,921. The business’s 50 day moving average price is $44.21. Medline has a twelve month low of $34.89 and a twelve month high of $50.88.

Medline (NASDAQ:MDLN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. The firm’s quarterly revenue was up 14.8% on a year-over-year basis.

Insider Activity

In other Medline news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. The trade was a 55.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrew J. Mills bought 2,586,206 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the transaction, the director owned 2,586,206 shares in the company, valued at approximately $74,999,974. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Institutional Investors Weigh In On Medline

Several institutional investors have recently made changes to their positions in MDLN. Sound Income Strategies LLC acquired a new position in Medline in the 4th quarter valued at $25,000. Entrust Financial LLC acquired a new position in Medline in the fourth quarter valued at about $26,000. NBC Securities Inc. bought a new stake in Medline during the fourth quarter worth about $28,000. Global Retirement Partners LLC bought a new stake in Medline during the fourth quarter worth about $31,000. Finally, North Star Investment Management Corp. acquired a new stake in Medline during the fourth quarter worth about $36,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Analyst upgrades — BMO raised its price target to $54 and gave an “Outperform” rating, signaling more upside from current levels. BMO raises PT to $54
• Positive Sentiment: Analyst upgrades — RBC raised its price target to $53 and also rates MDLN “Outperform,” reinforcing buy-side momentum following the results. RBC raises PT to $53
• Positive Sentiment: Revenue beat and constructive 2026 guidance — Q4 sales of ~$7.79B topped estimates and full‑year 2026 guidance calls for organic sales growth of 8–9% and Adjusted EBITDA of $3.5–3.6B; management highlighted $2.4B in new customer signings and completion of the IPO. Medline Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Institutional demand and IPO momentum — filings and data show large institutional allocations and follow-on positioning by major investors, which supports liquidity and buy-side interest post-IPO. Quiver Quant: Medline Reports Strong 2025 Results
• Neutral Sentiment: Conference call / transcript — the earnings call transcript is available for detail on margin drivers, customer wins and cost assumptions; useful for active investors to parse the guidance assumptions. Earnings call transcript
• Neutral Sentiment: Valuation discussion — post-earnings coverage is re‑pricing MDLN into the public comps; several outlets are assessing valuation after the early share momentum. Yahoo: Assessing Medline valuation
• Negative Sentiment: EPS miss and profitability headwinds — MDLN reported ($0.01) EPS vs. a ~$0.24 consensus, missing estimates; Q4 net income fell ~37.7% year/year driven by higher cost of goods sold (tariffs) and IPO/operating expenses. MarketBeat: MDLN earnings summary
• Negative Sentiment: Margin pressure and cost volatility — higher tariffs, inventory/cost increases and continued investments (headcount, automation) are compressing margins near term; watch whether gross margin recovers versus expected cost headwinds. MassDevice coverage
• Negative Sentiment: Insider and sponsor sales noted — secondary transactions and some large sponsor sell‑side activity were disclosed around the IPO, which can add supply pressure even as institutions load positions. QuiverQuant insider & institutional activity

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.